Becton, Dickinson and Company
One Becton Drive
Franklin Lakes
New Jersey
07417
United States
Tel: 201-847-6800
Fax: 201-847-6475
Website: http://www.bd.com/
864 articles about Becton, Dickinson and Company
-
BD to Sell Surgical Instrumentation Platform to STERIS
6/20/2023
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has signed a definitive agreement to sell its Surgical Instrumentation platform to STERIS.
-
BD Launches New Robotic System to Automate Clinical Flow Cytometry
6/12/2023
BD, a leading global medical technology company, announced the worldwide commercial launch of a new automated instrument that prepares samples for clinical diagnostics using flow cytometry, enabling a complete "walkaway" workflow solution designed to improve standardization and reproducibility in cellular diagnostics.
-
BD Advances Prefilled Flush Syringe with Integrated 'Scrub-the-Hub' Innovation
5/23/2023
BD, a leading global medical technology company, announced expanded customer availability of an all-in-one prefilled flush syringe with an integrated disinfection unit designed to reinforce compliance to infection prevention guidelines and simplify nursing workflow.
-
BD Launches World's First Spectral Cell Sorter with High-Speed Cell Imaging
5/18/2023
BD (Becton, Dickinson and Company) announced the worldwide commercial launch of a new-to-world cell sorting instrument featuring two breakthrough technologies that enable researchers to uncover more detailed information about cells that was previously invisible in traditional flow cytometry experiments.
-
AHF: Pharma Companies Scrapping HIV Diagnostics Endangers Patients
5/17/2023
AIDS Healthcare Foundation supports an appeal by Médecins Sans Frontières urging Abbott Laboratories and Becton Dickinson to continue production of equipment and consumables for point-of-care CD4 machines. Both companies have announced that they will phase out the production of cartridges and devices over the coming years, including Abbott’s Pima CD4 analyzers, which AHF widely uses around the world.
-
BD Gains 510(k) Clearance of Artificial Intelligence Software for MRSA Diagnostics
5/16/2023
BD (Becton, Dickinson and Company) today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the new BD Kiestra™ Methicillin-resistant Staphylococcus aureus (MRSA) imaging application that uses artificial intelligence (AI) to interpret bacterial growth and release negative specimens with minimal human interaction.
-
BD Reports Second Quarter Fiscal 2023 Financial Results
5/4/2023
BD, a leading global medical technology company, announced results for its second quarter of fiscal 2023, which ended March 31, 2023.
-
BD to Present at Bank of America Securities 2023 Health Care Conference
4/26/2023
BD, a leading global medical technology company, announced that it will present at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023 at 11:00 am Eastern Time.
-
BD Board Declares Dividend - April 25, 2023
4/25/2023
The Board of Directors of BD has declared a quarterly dividend of $0.91 per common share, payable on June 30, 2023 to holders of record on June 9, 2023.
-
BD Recognized by Forbes as a Best Employer for Diversity in 2023 List
4/25/2023
BD, a leading global medical technology company, announced that it has been recognized by Forbes as one of the leading employers in the U.S. for diversity.
-
BD Introduces Advanced Ultrasound Technology to Help Drive First-Stick Success for IV Insertions
4/11/2023
BD, a leading global medical technology company, launched a new, easy-to-use advanced ultrasound device with a specialized probe designed to provide clinicians with optimal IV placement.
-
BD to Announce Financial Results for its Second Quarter of Fiscal 2023
4/6/2023
BD, a leading global medical technology company, announced that it will report financial results for its second quarter of fiscal year 2023 on Thursday, May 4, 2023.
-
Michelle Quinn Named General Counsel for BD
4/3/2023
BD, a leading global medical technology company, announced that Michelle Quinn has been named executive vice president and general counsel for the company, effective April 1.
-
BD Receives FDA 510(k) Clearance for First-of-Its-Kind High-Throughput Diagnostic Test for Infectious Vaginitis
3/16/2023
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD Vaginal Panel on the BD COR™ System.
-
BD to Present at Barclays Global Healthcare Conference
3/1/2023
BD, a leading global medical technology company, announced that it will present at the Barclays Global Healthcare Conference on Wednesday, March 15, 2023 at 9:00 am Eastern Time.
-
BD to Present at Cowen 43rd Annual Healthcare Conference
2/21/2023
BD, a leading global medical technology company, announced that it will present at the Cowen 43rd Annual Healthcare Conference on Monday, March 6, 2023 at 9:50 am Eastern Time.
-
BD Named as One of America's Best Large Employers
2/15/2023
BD, a leading global medical technology company, announced that the company has been named to America's Best Large Employers List 2023 by Forbes, furthering its progress against the company's environmental, social and governance strategy.
-
BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery
2/3/2023
BD (Becton, Dickinson and Company) today announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research.
-
BD Reports First Quarter Fiscal 2023 Financial Results
2/2/2023
BD, a leading global medical technology company, announced results for its first quarter of fiscal 2023, which ended December 31, 2022.
-
BD Publishes 2022 Cybersecurity Annual Report
1/25/2023
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released its third annual cybersecurity report to update stakeholders about the company's ongoing efforts to advance cybersecurity maturity, protect against cyberattacks and empower customers with information about cyber risks and vulnerabilities.